Azetidinones as Zinc‐Binding Groups to Design Selective HDAC8 Inhibitors

2‐Azetidinones, commonly known as β‐lactams, are well‐known heterocyclic compounds. Herein we described the synthesis and biological evaluation of a series of novel β‐lactams. In vitro inhibition assays against HDAC isoforms showed an interesting isoform‐selectivity of these compounds towards HDAC6 and HDAC8. The isoform selectivity changed in response to modification of the azetidinone‐ring nitrogen atom substituent. The presence of an N‐thiomethyl group is a prerequisite for the activity of these compounds in the micromolar range towards HDAC8.

[1]  A. Mirsky,et al.  ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. H. Schlessinger,et al.  A novel method of preparing alpha-substituted hydracrylate and acrylate esters , 1973 .

[3]  T. Aida,et al.  Cyclization reactions of 4-(3′-butenyl)azetidin-2-one a route to the carbopenam ring system , 1979 .

[4]  H. Hoberg,et al.  Stöchiometrische und katalytische CC-verknüpfungen zwischen 1,3-butadien und phenylisocyanat an nickel(0)-komplexen , 1987 .

[5]  J. Clark,et al.  Cloning and characterization of a novel human histone deacetylase, HDAC8. , 2000, The Biochemical journal.

[6]  James D. Winkler,et al.  Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor* , 2000, The Journal of Biological Chemistry.

[7]  V. Kiermer,et al.  The emerging role of class II histone deacetylases. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[8]  M. Konaklieva.  β-Lactams as Inhibitors of Serine Enzymes , 2002 .

[9]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[10]  M. Mori,et al.  Synthesis of 3-alkoxycarbonyl-1beta-methylcarbapenem by using the palladium-catalyzed C-N bond-forming reaction between vinyl halide and beta-lactam nitrogen. , 2003, The Journal of organic chemistry.

[11]  T. Kummalue,et al.  The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain , 2003, Molecular and Cellular Biology.

[12]  L. Schwartz,et al.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  E. Lukevics,,et al.  Design of β-lactams with mechanism based nonantibacterial activities , 2003 .

[14]  R. De Francesco,et al.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  V. Castronovo,et al.  Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. , 2004, The American journal of pathology.

[16]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[17]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[18]  T. A. Ayers,et al.  Diastereoselective alkylation of beta-amino esters: structural and rate studies reveal alkylations of hexameric lithium enolates. , 2004, Journal of the American Chemical Society.

[19]  F. Becker,et al.  Synthesis of anticancer β-lactams: mechanism of action , 2004 .

[20]  Eric Verdin,et al.  Histone deacetylase HDAC8 associates with smooth muscle α‐actin and is essential for smooth muscle cell contractility , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  K. Bhalla.  Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Garbisa,et al.  4-Alkyliden-beta-lactams conjugated to polyphenols: synthesis and inhibitory activity. , 2005, Bioorganic & medicinal chemistry.

[23]  G. Giannini,et al.  Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. , 2005, Journal of medicinal chemistry.

[24]  H. Pritzkow,et al.  Bridging β‐Lactam Coordination at Dinuclear Zinc Sites , 2005 .

[25]  G. Musumarra,et al.  Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria. , 2006, Journal of medicinal chemistry.

[26]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[27]  S. Garbisa,et al.  Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden-β-lactam with a Galloyl Moiety , 2006, Journal of Pharmacology and Experimental Therapeutics.

[28]  R. Ficner,et al.  Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. , 2006, Journal of biotechnology.

[29]  E. Seto,et al.  Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation , 2006, Molecular and Cellular Biology.

[30]  Ravi Varala,et al.  Molecular iodine-catalyzed efficient N-Cbz protection of amines , 2007 .

[31]  R. Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy , 2007, Expert opinion on investigational drugs.

[32]  R. De Francesco,et al.  Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complex , 2007, EMBO reports.

[33]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[34]  Eric Verdin,et al.  Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[35]  B. Långström,et al.  Synthesis of [11C]/[13C]acrylamides by palladium-mediated carbonylation , 2007 .

[36]  R. Deana,et al.  Inhibitory effect by new monocyclic 4-alkyliden-beta-lactam compounds on human platelet activation , 2007, Platelets.

[37]  Seikwan Oh,et al.  Synthesis of New β-Lactam Analogs and Evaluation of Their Histone Deacetylase (HDAC) Activity , 2007 .

[38]  Y. Oda,et al.  Expression profile of class I histone deacetylases in human cancer tissues. , 2007, Oncology reports.

[39]  J. Buggy,et al.  Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation , 2008, Leukemia.

[40]  Di Chen,et al.  Anti-tumor activity of N-thiolated beta-lactam antibiotics. , 2008, Cancer letters.

[41]  M. K. Pflum,et al.  Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.

[42]  J. Marchand-Brynaert,et al.  3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[43]  S. Hrelia,et al.  New Polyphenolic β‐Lactams with Antioxidant Activity , 2008, Chemistry & biodiversity.

[44]  P. Wipf,et al.  Titanocene(III)-catalyzed formation of indolines and azaindolines. , 2008, Organic letters.

[45]  F. Zunino,et al.  Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. , 2009, European journal of medicinal chemistry.

[46]  G. Giannini,et al.  N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[47]  Barbara Hero,et al.  Histone Deacetylase 8 in Neuroblastoma Tumorigenesis , 2009, Clinical Cancer Research.

[48]  G. Giannini,et al.  Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.